Platelet activating factor levels and metabolism in tangier disease: a case study

被引:4
|
作者
Kolovou, Vana [1 ,2 ,3 ]
Papakonstantinou, Vasiliki D. [3 ]
Stamatakis, George [3 ]
Verouti, Sophia N. [3 ]
Xanthopoulou, Marianna N. [4 ]
Kolovou, Genovefa [1 ,2 ]
Demopoulos, Constantinos A. [3 ]
机构
[1] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece
[2] Onassis Cardiac Surg Ctr, Mol Immunol Lab, Athens, Greece
[3] Univ Athens, Fac Chem, Biochem Lab, Athens 11528, Greece
[4] Harokopio Univ, Dept Sci Nutr Dietet, Athens, Greece
关键词
PAF; Tangier Disease; Atherosclerosis; Lp-PLA(2); PAF-AH; Lyso-PAF-AT; PAF-CPT; ACETYLHYDROLASE PAF-AH; CASSETTE TRANSPORTER 1; DENSITY-LIPOPROTEIN; PHOSPHOLIPASE A(2); PLASMA; BINDING; CHOLESTEROL; BLOOD; VIVO; LEUKOCYTES;
D O I
10.1186/1476-511X-11-89
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A(2) (Lp-PLA(2)) in plasma and regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for 50% aggregation (EC50) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and thrombin, and the activities of PAF metabolic enzymes Lp-PLA(2), PAF-AH, Lyso-PAF-AT and PAF-CPT. Methods: The EC50 value of PRP was measured by an aggregometer. The determination of the specific activity of PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA(2) was made after an in vitro enzymatic assay from the decay of radioactive PAF. Results: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA(2) activity in plasma compared to healthy women. The EC50 of PAF and Thrombin were higher compared to healthy women. Conclusion: The increased Lp-PLA(2) activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain the decreased bound-PAF level in TD patient and the EC50 of PAF. However, total PAF is in a normal range and this probably can explain one of the reasons this TD patient has no CAD.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Platelet-activating factor levels in term and preterm human milk
    Akisü, M
    Kültürsay, N
    Özkayin, N
    Çoker, I
    Hüseyinov, A
    BIOLOGY OF THE NEONATE, 1998, 74 (04): : 289 - 293
  • [42] PLATELET-ACTIVATING-FACTOR LEVELS IN HUMAN FOLLICULAR AND AMNIOTIC FLUIDS
    BERNAL, AL
    NEWMAN, GE
    PHIZACKERLEY, PJR
    LAIRD, E
    ROSS, C
    BARLOW, DH
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1992, 46 (01) : 39 - 44
  • [43] FIBRONECTIN LEVELS IN PLASMA AFTER PLATELET-ACTIVATING FACTOR INHALATION
    NABE, M
    MIYAGAWA, H
    HOPP, RJ
    AGRAWAL, DK
    BEWTRA, AK
    TOWNLEY, RG
    INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1990, 91 (02): : 113 - 117
  • [44] Pentoxifylline decreases brain levels of platelet activating factor in murine AIDS
    Sei, Y
    Nishida, K
    Kustova, Y
    Markey, SP
    Morse, HC
    Basile, AS
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 325 (01) : 81 - 84
  • [45] Platelet Activating Factor Acetylhydrolase Levels at Baseline and during Allergic Reactions
    Kattan, Jacob D.
    Kraus, Thomas
    Moran, Thomas
    Sampson, Hugh A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB48 - AB48
  • [46] Cholesterol and apolipoprotein B metabolism in Tangier disease
    Schaefer, EJ
    Brousseau, ME
    Diffenderfer, MR
    Cohn, JS
    Welty, FK
    O'Connor, JJ
    Dolnikowski, GG
    Wang, J
    Hegele, RA
    Jones, PJ
    CIRCULATION, 2001, 104 (17) : 313 - 313
  • [47] Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis
    Vadas, Peter
    Perelman, Boris
    Liss, Gary
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (01) : 144 - 149
  • [48] GLOMERULAR PLATELET-ACTIVATING FACTOR LEVELS AND ORIGIN IN EXPERIMENTAL GLOMERULONEPHRITIS
    LIANOS, EA
    ZANGLIS, A
    KIDNEY INTERNATIONAL, 1990, 37 (02) : 736 - 740
  • [49] PLATELET-ACTIVATING FACTOR AND INFLAMMATORY BOWEL-DISEASE
    STENSON, WF
    GASTROENTEROLOGY, 1988, 95 (05) : 1416 - 1419
  • [50] PLATELET-ACTIVATING-FACTOR AND CROHNS-DISEASE - REPLY
    ELIAKIM, R
    RACHMILEWITZ, D
    GUT, 1994, 35 (01) : 141 - 141